CURRENT STATUS OF CLAIMS WITH CLAIM AMENDMENTS

1-7. **Canceled.**

8. **(Previously presented)** A method of directing an antimicrobial peptide in vivo to prostate tissue, comprising administering a chimeric prostate-homing pro-apoptotic peptide, which comprises a prostate-homing peptide linked to an antimicrobial peptide,

said chimeric peptide exhibiting selective toxicity to prostate tissue, and

said antimicrobial peptide having low mammalian cell toxicity when not linked to said prostate-homing peptide.

9. **(Original)** The method of claim 8, wherein said prostate-homing peptide comprises the sequence SMSIARL (SEQ ID NO: 207), or a functionally equivalent sequence.

10-12. **Canceled.**

13. **(Previously presented)** A method of selectively inducing apoptosis in prostate tissue in vivo, comprising administering to a subject a chimeric prostate-homing pro-apoptotic peptide, which comprises a prostate-homing peptide linked to an antimicrobial peptide,

said chimeric peptide exhibiting selective toxicity to prostate tissue, and

said antimicrobial peptide having low mammalian cell toxicity when not linked to said prostate-homing peptide.

14. **(Original)** The method of claim 13, wherein said prostate-homing peptide comprises the sequence SMSIARL (SEQ ID NO: 207), or a functionally equivalent sequence.

15-22. **Canceled.**

23. **(Previously presented)** A method of selectively inducing apoptosis in normal prostate tissue in vivo, comprising administering to a subject a chimeric prostate-homing pro-apoptotic peptide, which comprises a prostate-homing peptide linked to an antimicrobial peptide,

said chimeric peptide exhibiting selective toxicity to normal prostate tissue, and

said antimicrobial peptide having low mammalian cell toxicity when not linked to said prostate-homing peptide.

24. **(Previously presented)** The method of claim 23, wherein said prostate-homing peptide comprises the sequence SMSIARL (SEQ ID NO: 207), or a functionally equivalent sequence.

25-27. **Canceled.**

28. **(New)** A method of directing an antimicrobial peptide in vivo to prostate tissue, comprising administering a chimeric prostate-homing pro-apoptotic peptide, which comprises a prostate-homing peptide linked to an antimicrobial peptide,

said chimeric peptide exhibiting selective toxicity to prostate tissue, and

said antimicrobial peptide having an amphipathic α-helical structure and having low mammalian cell toxicity when not linked to said prostate-homing peptide.

29. **(New)** The method of claim 28, wherein said antimicrobial peptide having an amphipathic α-helical structure comprises the sequence $_D$(KLAKLAK)$_2$.

30. **(New)** A method of selectively inducing apoptosis in prostate tissue in vivo, comprising administering to a subject a chimeric prostate-homing pro-apoptotic peptide, which comprises a prostate-homing peptide linked to an antimicrobial peptide,

said chimeric peptide exhibiting selective toxicity to prostate tissue, and

said antimicrobial peptide having an amphipathic α-helical structure and having low mammalian cell toxicity when not linked to said prostate-homing peptide.

31. **(New)** The method of claim 30, wherein said antimicrobial peptide having an amphipathic α-helical structure comprises the sequence $_D$(KLAKLAK)$_2$.

32. **(New)** A method of selectively inducing apoptosis in normal prostate tissue in vivo, comprising administering to a subject a chimeric prostate-homing pro-apoptotic peptide, which comprises a prostate-homing peptide linked to an antimicrobial peptide,

said chimeric peptide exhibiting selective toxicity to normal prostate tissue, and

said antimicrobial peptide having an amphipathic α-helical structure and having low mammalian cell toxicity when not linked to said prostate-homing peptide.

33. (**New**) The method of claim 32, wherein said antimicrobial peptide having an amphipathic α-helical structure comprises the sequence $_D$(KLAKLAK)$_2$.